Aeglea BioTherapeutics (AGLE) Receives News Impact Score of -0.01
Media stories about Aeglea BioTherapeutics (NASDAQ:AGLE) have trended somewhat negative on Wednesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a coverage optimism score of -0.01 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.0884187988758 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Aeglea BioTherapeutics (NASDAQ AGLE) traded up 6.07% during trading on Wednesday, reaching $4.54. The company’s stock had a trading volume of 29,491 shares. The company’s market cap is $74.69 million. Aeglea BioTherapeutics has a 52-week low of $2.81 and a 52-week high of $10.34. The firm’s 50-day moving average is $3.47 and its 200 day moving average is $5.05.
A number of research analysts recently weighed in on AGLE shares. TheStreet downgraded Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research note on Friday, May 26th. ValuEngine raised Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research raised Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Thursday, August 3rd.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.